Encelta AG
Encelta’s allogeneic T cells are engineered to retain full TCR function while eliminating the risk of GvHD, enabling safe, off-the-shelf use across patients. Designed to work in combination with T-cell engagers (TCEs), they restore anti-tumor immunity in patients unresponsive to TCEs alone.This off-the-shelf product offers simple logistics and outpatient accessibility, overcoming the challenges faced by the current autologous cell therapies.
Date, time and room information
May 6, 14:15 - 14:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Encelta_ Unlocking the Curative Potential of T- cell Engagers (TCEs)
Speaker information
| Name | Position | Institution |
|---|---|---|
| Edo Kapetanovic | CEO/CSO |
Further information for the sponsor website
